Putnam Investments LLC Immuno Gen, Inc. Transaction History

Putnam Investments LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 14, 2023	SELL	$14.09 - $19.87 $6.79 Million - $9.58 Million	-481,934 Reduced 86.52%	75,073 $1.19 Million
Q2 2023 Aug 14, 2023	SELL	$3.75 - $20.05 $2.23 Million - $11.9 Million	-594,146 Reduced 51.61%	557,007 $10.5 Million
Q1 2023 May 22, 2023	BUY	$3.67 - $4.92 $109,516 - $146,817	29,841 Added 2.66%	1,151,153 $4.42 Million
Q4 2022 Feb 14, 2023	BUY	$4.55 - $6.31 $410,501 - $569,288	90,220 Added 8.75%	1,121,312 $5.56 Million
Q3 2022 Nov 14, 2022	BUY	$4.48 - $6.47 $3.68 Million - $5.31 Million	820,722 Added 390.13%	1,031,092 $4.93 Million

Q2 2022 Aug 15, 2022	SELL	$3.15 - $5.76 $8,227 - $15,045	-2,612 Reduced 1.23%	210,370 $946,000
Q1 2022 May 16, 2022	SELL	$4.26 - $7.48 $68,918 - $121,011	-16,178 Reduced 7.06%	212,982 $1.01 Million
Q4 2021 Feb 14, 2022	BUY	$4.75 - $7.5 $1.09 Million - $1.72 Million	229,160 New	229,160 $1.7 Million
Q3 2018 Nov 14, 2018	SELL	$8.6 - $11.26 $461,003 - $603,592	-53,605 Closed	0 $0
Q2 2018 Aug 14, 2018	BUY	$9.52 - $12.15 $510,319 - $651,300	53,605 New	53,605 $522,000

1.41M

Ticker IMGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 220,712,992
Description
ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...

Get notified when there are updates to the investment portfolio of Putnam Investments LLC, based on Form 13F filings with the SEC.

Stay updated on Putnam Investments LLC with notifications on news.